Anda di halaman 1dari 22

PARAGANGLIOMA

PARAGANGLIOMA
PARAGANGLIOMA
- Merupakan bagian dari NET ( Neuroendocrine Tumor), berasal dari sel kromafin yang memproduksi
katekolamin dimana terbagi 2 jenis Pheochomocytoma (kelenjar adrenal) dan paraganglioma (extra adrenal)
- Tumor yang jarang (2-8 tiap 1 juta pertahun), 10% didiagnosis pada usia anak

- Sebagian besar Paraganglioma/ extra adrenal paraganglioma tumbuh lambat/jinak, dapat berpotensi
metastasis (20-40%), 15% kasus bisa menjadi ganas
- metastase ke tulang, paru, hepar dan kelenjar limfe

- -Bsa terdapat pada seluruh bagian tubuh, Sebagian besar di abdomen

- Ada 2 tipe

- 1. Paragangglioma fungsional (simpatetik). Memproduksi katekolamin, 85% berada di bawah diafragma

- 2. Paraganglioma non fungsional (parasimpatetik) paling sering ditemukan di kepala dan leher. 95% tidak
memproduksi katekolamin
- syndrome terkait PCC/PGL : multiple endocrine neoplasia (MEN) type 2, Von Hippel–Lindau (VHL)
type 2, neurofibromatosis (NF) type 1, and the paraganglioma–pheochromocytoma syndromes (SDHx)
MANISFESTASI KLINIS
 tumor yang mensekresi katekolamin menimbulkan gejala hipertensi, nyeri kepala, berkeringat,
berdebar, cemas, tremor, penurunan berat badan, mual, lemas atau hipotensi postural dengan derajat
bervariasi
Tumor yang mensekresi dopamine biasanya asimptomatik sampai efek masa muncul, pada
paraganglioma kepala dan leher menyebabkan disfagia, serak, nyeri dan gangguan pendengaran
FAKTRO RISIKO
- 80% kasus PGG/PCC anak diturunkan

- Pasien dengan mutase genetik perlu pematuan rekurensi dan malignansi

- Usia saat presentasi 11-13 tahun

- Laki-laki lebih banyak dari perempuan


STAGING
Stage I: The tumor is smaller than 5 cm. It is located only in the adrenal gland. No other organs are involved (T1, N0,
M0)

Stage II: The tumor is 5 cm or more in size, and it has not grown beyond the adrenal gland. Or, it is a paraganglioma
that causes symptoms. No other organs are involved. (T2, N0, M0)

Stage III: Any of the following applies:


•The tumor is smaller than 5 cm. It is located only in the adrenal gland. The cancer involves the regional lymph nodes.
(T1, N1, M0)
•The tumor is 5 cm or larger but does not grow beyond the adrenal gland. Or, it is a paraganglioma that causes
symptoms. The cancer involves the regional lymph nodes. (T2, N1, M0)
•The tumor is any size and invades nearby tissues, such as the liver, pancreas, spleen, or kidneys. (T3, any N, M0)

Stage IV: There is metastasis. (Any T, any N, M1)


DIAGNOSIS
 pengukuran free metanephrine plasma
TATALAKSANA
1. MENGONTROL HORMON DAN EFEKNYA

2. PEMBEDAHAN

3. RADIASI

4. KEMOTERAPI

5. TARGETED THERAPHY : Tyrosine Kinase Inhibitor cabozantinib (Cometriq), sunitinib


(Sutent), and axitinib (Inlyta)

6. IMUNOTERAPI ( dalam penelitian ) pembrolizumab (Keytruda)


KEMOTERAPI
 Regimen CVD (Cyclophosphamides, Vincristine, Decarbazine)

 pertama di 1985 oleh Keiser et al


PROGNOSIS
- PGG malignant buruk dengan 5 y survival rate < 50%

- malignant PGG : adanya lesi metastase

- faktor prediktor metastase : ukuran > 5-6 cm, ekstra adrenal, fenotip noradrenergic, mutasi gen SDH
A/B, tumor berulang, usia <20 th saat terdiagnosis

- rekurensi 12-38% kasus


RENCANA UNTUK PASIEN
Validated prognostic pathological parameters for malignant PCCs/PGLs are lacking, although some
risk stratification systems have been described, such as The Pheochromocytoma of the Adrenal Gland
Scaled Score (PASS) [26] and the more recently extended Grading of Adrenal Pheochromocytoma and
Paraganglioma (GAPP) [27]. However, as reviewed [28], these score systems have limited predictive
ability. Nevertheless, the ’rule-out’ value of both algorithms seems promising in order to exclude
future metastatic potential: PCCs with a PASS score
Tyrosine—dopa (enzim tyrosine hydroxylase)– dopamine—norefinefrin---eoinefrin

PCC : epinefrin dan norepinefrin

PGL norefinefrin dan dopamin


Title Lorem Ipsum
Q1 Q2 Q3 Q4
Lorem ipsum et tula lorem Lorem ipsum et tula lorem Lorem ipsum et tula lorem Lorem ipsum et tula lorem
ipsum et lorem ipsum ipsum et lorem ipsum ipsum et lorem ipsum ipsum et lorem ipsum

Lorem ipsum et tula lorem Lorem ipsum et tula lorem Lorem ipsum et tula lorem Lorem ipsum et tula lorem
ipsum et lorem ipsum ipsum et lorem ipsum ipsum et lorem ipsum ipsum et lorem ipsum

Lorem ipsum et tula lorem Lorem ipsum et tula lorem Lorem ipsum et tula lorem Lorem ipsum et tula lorem
ipsum et lorem ipsum ipsum et lorem ipsum ipsum et lorem ipsum ipsum et lorem ipsum

Anda mungkin juga menyukai